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Abstract: Introduction: Systemic sclerosis (SSc) is a rare conjunctive tissue disorder characterized by fibrosis of the skin 
and internal organs, and vascular obliteration phenomena. Patients with SSc often experience elevated symptoms of psy-
chological distress, determined by the disfiguration, the pain, the fatigue sensation, and the difficult in daily life occupa-
tions. The characteristics of the disease may influence the perceived quality of life (QoL) in people with SSc.  
Methods: This is a narrative review aiming to define the amount of impairment of Quality of Life in patients with Sys-
temic Sclerosis and the component of this impairment due to depressive or other psychiatric symptoms. The search of the 
significant articles was carried out in PubMed for the key words “Psychiatric symptoms and Systemic Sclerosis”; “Quality 
of life and Systemic Sclerosis”; “Depressive Disorders and Systemic Sclerosis”.  
Results: Psychiatric symptoms are frequents in patients with SSc, but pain, fatigue, disability, body changes don’t appear 
to explain the high prevalence of psychiatric comorbidity in SSc. Many studies founded a significant impairment in SSc 
patients’ QoL, and despite the undeniable correlation between physical symptoms and SSc patients’ QoL, mental health 
was found significantly impaired. 
Discussion: The high rate of depression seems to strictly correlate with poor quality of life, and this finding needs more 
research to establish the cause of such a correlation. Patients’ point of view regarding their health-related QoL could help 
physicians to enlarge the knowledge about physical and mental correlates of the disease, and to fit therapies as patient re-
quired. Particular attention must be given to provide the patient with correct information, in order to mitigate the anxious 
state on disease course, and to enhance coping skills of the patients.  
Keywords: Systemic sclerosis, psychiatric symptoms, depressive disorder, quality of life. 
INTRODUCTION 
Systemic sclerosis (SSc) is a rare conjunctive tissue   
disorder characterized by fibrosis of the skin and internal 
organs, and vascular obliteration phenomena. Those features 
are responsible for increased morbidity and mortality. Skin 
afflictions cause major body changes, which may contribute 
to the occurrence of psychological disturbances such as 
anxiety and depression [1]. Central Nervous System (CNS) 
is involved in SSc due to the consequence of functional and 
structural abnormalities of small blood vessels, signifying a 
form of CNS vasculopathy [2]. Similar to other rheuma-
tologic diseases, SSc is chronic, invaliding and it needs 
treatments that may have disrupting adverse effects (corti-
costeroids, interferon, immunosuppressants). Moreover, it is 
a heterogeneous disorder, with different clinical features 
from a skin-localized involvement to a multi-organic disease 
with lungs, kidneys, hearth, musculoskeletal and gastrointes-
tinal systems failure, until a complete functional disability 
[3, 4]. Two major subtypes have been described depending 
on the extent of skin lesions: limited cutaneous SSc (lcSSc) 
and diffuse cutaneous (dcSSc). Poorer outcome is generally 
associated with the diffuse form, characterized by a   
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precocious visceral failure, which may be absent or tardive 
in the limited form. Given the heterogeneity of the disease 
and its insidious course, diagnosis often is done late. 
Patients with SSc often experience elevated symptoms of 
psychological distress, determined by changes in physical 
appearance, pain, fatigue sensation, and difficult in daily life 
occupations. All the characteristics of the disease may influ-
ence the perceived QoL in people with SSc.  
This is a narrative review that seeks to analyze the results 
of studies on Psychiatric symptoms and QoL in Systemic 
Sclerosis, aiming to define the amount of impairment of QoL 
in patients with Systemic Sclerosis and the extent of this 
impairment due to depressive or other psychiatric symptoms. 
METHODS 
The search of the significant articles was carried out in 
PubMed for the key words “Psychiatric symptoms and Sys-
temic Sclerosis”; “Quality of life and Systemic Sclerosis”; 
“Depressive Disorders and Systemic Sclerosis”. We found 
28 relevant articles containing the terms “psychiatric symp-
toms” or “depression and Systemic Sclerosis” (15 were ex-
cluded because in six cases the argument treated was not 
pertinent, five were letter to editor, three were case-reports, 
one was in French), 42 articles containing the terms “Quality 
of Life and Systemic Sclerosis” (18 were excluded since 
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RESULTS 
Psychiatric Symptoms in Systemic Sclerosis 
Depressive symptoms are frequents in patients with SSc, 
with prevalence of major depressive disorder ranged from 17 
to 69% of SSc people [5-8]. A review by Thombs and col-
leagues [9] found a prevalence of clinically significant de-
pressive symptoms in 51–65% based on two studies that 
used a Beck Depression Inventory (BDI) score 10 and 46–
56% based on two studies that used a BDI score 11; four 
other studies that used different assessment tools detected a 
prevalence of depression in 36–43%. The authors underlined 
the lack of studies using a clinical structured interview; how-
ever, the findings were consistently high compared with 
other medical patient groups assessed with the same instru-
ments and cutoffs.  
Using The Center for Epidemiological Studies Depres-
sion Scale (CES-D), a 20-item self-report measure com-
monly used as a depression screening and research tool in 
rheumatic diseases, Thombs carried out a case-control study 
[10] on 403 patients with SSc and 403 non-medical respon-
dents to an Internet depression survey, matched on total 
CES-D score, age, race/ethnicity, and sex. The mean total 
CES-D score for both the SSc and Internet groups was 14.0 
points; over one-third of each group scored 16 points on the 
CES-D (148 [36.7%] of 403), and over a quarter of patients 
scored 19 points (110 [27.3%] of 403). Patients with SSc 
reported significantly higher frequencies (moderate to large 
effect size; P < 0.01) on 4 CES-D somatic symptom items: 
bothered, appetite, effort, and sleep, but high rates of depres-
sive symptoms in SSc are not due to bias related to the report 
of somatic symptoms. 
A recent cross-sectional study published by Baubet and 
colleagues [7] on 100 SSc patients, both hospitalized and 
outpatients, was assessed using a structured clinical inter-
view, the Mini International Neuropsychiatric Interview 
(MINI), and a self-reporting questionnaire, the Hospital 
Anxiety and Depression Scale (HADS). As assessed by the 
MINI, 19% [95% confidence interval 12-28%] of all SSc 
patients were currently experiencing a major depressive epi-
sode (MDE), 56% [46-65%] had a lifetime history of MDE 
and 14% [8-22%] had current dysthymia. Current MDE was 
more prevalent among hospitalized patients than among out-
patients (28% versus 10%, p=0.02). Specific anxiety disor-
ders were diagnosed in 37% [28-47%]. Less than 50% of the 
SSc patients with mood disorders received psychiatric treat-
ment. Legendre and colleagues [11] carried out a prospective 
study on a small cohort (42 patients, including 18 with dif-
fuse cutaneous scleroderma and 24 with limited cutaneous 
scleroderma). Mean age was 57 +/- 13 years, mean disease 
duration was 10.2 +/- 8 years, and the mean functional 
Health Assessment Questionnaire score was 0.682 +/- 0.649. 
The Montgomery-Asberg Depression Rating Scale 
(MADRS) and the Hamilton Anxiety Rating Scale were used 
to evaluate depression and anxiety, respectively; 43% pa-
tients met criteria for depression (in 26% scored as moderate 
to severe), 64% patients met criteria for minor anxiety and 
19% for major anxiety. Depression and anxiety were 
strongly correlated with each other (r = 0.89; P < 0.0001). 
The MADRS score was significantly higher in the patients 
with pulmonary restrictive disease (P = 0.009) but was not 
associated with the extent of skin involvement, organ in-
volvement, or disability. 
Compared to Rheumatoid Arthritis, SSc patients have 
less bodily pain and disability, but they tend to report higher 
depressive symptom scores [12]; moreover, SSc patients 
show the presence of significantly higher psychiatric symp-
toms of anxiety and depression than patients with other seri-
ous skin conditions, such as melanocytic naevi or melanoma 
[13].  
Pain, fatigue, disability, body does not appear to explain 
the high prevalence of psychiatric comorbidity in SSc, and 
there are a very few studies that investigated the pathophysi-
ology of such a phenomenon. Goldenberg proposed an in-
flammatory/immune mechanism, common at all rheuma-
tologic diseases, on a fibromyalgia-based model [14].  
Some early studies correlated depressive symptoms, 
functional impairment, and personality traits with SSc. Roca, 
Whigley & White [8] assessed 54 SSc patients with the Beck 
Depression Inventory, the Neuroticism-Extraversion-
Openness Personality Inventory, the Health Assessment 
Questionnaire, and the Psychosocial Adjustment to Illness 
Scale. Nearly half of the patients had mild depressive symp-
toms, and an additional 17% had symptoms in the moderate-
to-severe range. Depressive symptoms were found to corre-
late with younger age, presence of digital ulceration, higher 
self-rate functional impairment, but there were highly sig-
nificant relationships between depression and aspects of per-
sonality, psychosocial adjustment to illness, and lack of so-
cial support.  
Similar findings, except regarding the lack of social sup-
port, were detected in an Italian study [15] on 111 SSc pa-
tients assessed by the Beck Depression Inventory (BDI) 
questionnaire, the scleroderma Health Assessment Question-
naire (sHAQ) and two additional questions assessing the 
patient’s familiar support and the social consequences of the 
patient’s change in physical appearance. Mild to severe de-
pressive symptoms were found in 33.4%. While on univari-
ate analysis many physical symptoms (such as the diffuse 
cutaneous form of the disease, lung involvement, pain, Ray-
naud’s phenomenon, ulcers and disease severity) were asso-
ciated with the presence of pathologic depressive symptoms, 
on multivariate analysis only the Visual Analog Scale for 
disease severity was correlated to BDI scores (p=0.016). 
Interestingly, social behavior changes due to SSc-related 
physical involvement were reported in 38% of patients with 
depressive symptoms (p=0,006) and were more likely to be 
observed in younger patients (p=0.001) with a more severe 
Raynaud’s phenomenon (p=0.013). 
Matsuura and colleagues [16] evaluated 50 SSc patients 
for factors associated with depressive symptoms using the 
Beck Depression Inventory (BDI), the Rheumatology Atti-
tude Index for measuring helplessness, the Sense of Coher-
ence (SOC) scale (a measure of an individual's resilience in 
the face of stress and capacity to cope with it), the modified 
Health Assessment Questionnaire for physical disability, 
working, and social function, support domains of Arthritis 
Impact Measurement Scales version 2, and a visual analog 
pain scale. They found depressive symptoms ranging from 
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were significantly correlated with low working ability, low 
social activity, low SOC, pain, and helplessness, and not 
associated with disease severity variables including skin 
score and internal organ involvement. Multiple regression 
analysis showed that a high level of helplessness and a low 
level of SOC might be closely associated with depressive 
symptoms in SSc.  
Depression and its cognitive correlates are important 
variables to understand the experience of the pain in a rheu-
matologic disorder: whereas the patient’s self-report of pain 
is only marginally related to the real severity of illness, it’s 
strongly associated with depression [12]. A cognitive corre-
late of depression is catastrophizing, which includes magni-
fication of pain-related symptoms, rumination about pain, 
feelings of helplessness, and pessimism about pain-related 
outcomes [17]. Catastrophizing in osteoarthritis patients 
shows associations with self-reported disability, pain behav-
iors, functional limitations [18], in rheumatoid arthritis it is 
relates to reduction in muscle mobility and strength [19], and 
to increased levels of disease activity [20]. The physiopa-
thological mechanism below those associations is not yet 
cleared; in particular is uncertain if there is any direct rela-
tionship between catastrophizing and hypothalamic-
pituitary-adrenal axis; an indirect evidence is that there is an 
increase in myocardial contractility in high-catastrophizing 
individuals [21]. From a psycho-social view, many research-
ers consider catastrophizing a maladaptive style of coping, 
derived from personality characteristics of insecure adult 
attachment cognitive style, directed to elicit a more solici-
tous attention from others: significant social support may 
reinforce high expression of pain, helplessness and depres-
sion [22]. This may lead catastrophizers to increase their 
attention levels to bodily sensations, painful stimuli, until 
obsessive anticipation of pain that determined an amplifica-
tion of pain [23, 24]. Catastrophizing in SSc patients was 
found more highly associated with greater reporting of affec-
tive pain among those with less formal education [25], but 
such a relationship remains unclear. In RA this finding was 
replicated, and it was shown a correlation between catastro-
phizing, low socioeconomic status, or social dysfunction 
[26].  
Another explanation may be that SSc, similar to other 
autoimmune diseases, is characterized by an enhancement of 
vulnerability to psychological distress, determined by the 
deregulation of auto-immune response. Such vulnerability 
may act as a predisposition to mood disorders [27].  
Until a few years ago, most researchers thought that 
scleroderma didn’t involve CNS. Because, despite the fre-
quency of psychiatric symptoms, neurological symptoms are 
rare. A functional magnetic resonance study on patients with 
fibromyalgia showed enhancement of activity in anterior 
cingulate and insular cortex during the experience of acute 
pain [28]: significantly, these regions of CNS are responsible 
of the affective processing of pain. More recent work sug-
gests that, the focus has been shifted to understand the con-
sequence of vascular and micro-vascular CNS involvement 
in SSc (hyperintense foci of variable size diffuse in white 
matter), and is thought to be a form of CNS vasculopathy, 
similar to the Systemic Lupus Erythematosus [2, 29]. Other 
autoimmune diseases have also cause characteristic pattern 
of cerebral perfusion anomalies related to mood disorders 
[30, 31]. Further studies will clarify the clinical correlates 
between psychiatric symptoms and SSc RM and SPECT 
imaging findings. 
QUALITY OF LIFE IN SYSTEMIC SCLEROSIS 
Although morbidity and mortality are the prominent out-
comes to determine the social impact of diseases, patient-
reported point of view on health-related QoL has become an 
interesting way to obtain information on the experience of 
disease, treatment efficacy and need of cares.  
QoL is a subjective, heterogeneous concept of well-being 
correlated with a number of factors, such as severity and 
duration of illness, use of medications and stress events. The 
subjective perception of QoL is now considered of great 
relevance to measure the outcomes in a chronic disease [32, 
33] particularly in those with high impairment and much 
impacted daily life [34]. It has become central to evaluating 
the effectiveness of treatments as well. 
To date, there have been few research on QoL in SSc, 
and most have a small size of sample: although SSc is a se-
vere, potentially devastating disease, it has a low prevalence. 
The central symptom of SSc is pain, due to various causes 
(arthritis, digital ulcerations, esophagitis, Raynaud’s phe-
nomenon, chronic diarrhea, etc.).  
A high correlation between pain and health-related QoL 
has been reported in SSc. In a prospective cross-sectional 
study of 89 SSc patients, Georges and colleagues [35] exam-
ined the impact of pain in the QoL of 89 SSc patients with 
either a limited (N=22) or a diffuse (N=67) form of SSc us-
ing two self-administered questionnaires, the French ver-
sions of the SSc health assessment questionnaire (HAQ) and 
the SF-36. The QoL as assessed by the SF-36 appeared re-
lated to the burden of clinical manifestations, in relation to 
the number of clinical involvements, the functional disability 
and the pain, with a high correlation between pain and 
health-related QoL. All the SF-36 subscale scores of SSc 
patients were lower than those already reported in general 
population. Both PCS (Physical component summary score) 
and MCS (Mental component summary score) of the SF-36 
were lower in diffuse than in limited SSc, which could be 
related to the disease extension. Therefore, although it might 
be obvious for any clinician, the effective control of the pain, 
which can be related to the presence of either RP, digital 
ulcerations, musculoskeletal or digestive involvement, 
should constitute the primary therapeutic goal to achieve a 
better QoL in SSc-treated patients. 
Bassel and colleagues recently published a paper [36]   
focused to identify symptoms of SSc that highly impacted 
patients’ ability to carry out daily activities. Using the   
Canadian Scleroderma Patient Survey of Health Concerns 
and Research Priorities, 464 SSc patients were asked about 
the frequency and impact of 69 SSc symptoms. The five 
symptoms more frequently experienced and associated with 
moderate to severe impact on daily activities were: fatigue 
(89 and 72%), Raynaud’s Phenomenon (86 and 67%), hand 
stiffness (81 and 59%), joint pain (81 and 64%) and   
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Another prominent symptom of SSc is the fatigue: such 
as other chronic, painful debilitating diseases, the most of the 
patients reported fatigue, which is a significant determinant 
of physical functioning [36, 37].  
QUALITY OF LIFE AND PSYCHOLOGICAL   
IMPAIRMENT IN SYSTEMIC SCLEROSIS  
The higher prevalence of unmet needs in SSc patients 
causes psychological, spiritual and existential problems. In 
fact, they are often unable to do the things they used to do; 
they worry about appearance, scared of disease progression 
and physical disability, and uncertain of their future [38, 39]. 
Such an anxious situation may produce chronic feelings of 
demoralization, uselessness, loss of control. In a systematic 
review of 12 studies on health-related QoL in SSc, Hudson 
and colleagues found significant impairment in SSc patients 
[40]. Despite the undeniable correlation between physical 
symptoms and SSc patients’ QoL (SF-36 Physical Compo-
nent Summary score was more than one SD below that of the 
general population), mental health was found significantly 
impaired (SF-36 Mental Component Summary score was 
approximately 0.5 SD below that of the general population). 
A recent address of study on QoL in SSc is focused on 
depression. QoL impairment and female sex were found as 
independent risk factors for depressive symptoms in a cross-
sectional study on 72 patients [59 female (82%), mean age 
59 years] carried out by Muller and colleagues [5]. Vali-
dated questionnaires, the Health Assessment Questionnaire 
(HAQ), EuroQol (EQ-5D) and the Center for Epidemiologic 
Studies Depression scale (CES-D) were utilized to measure 
disability, quality of life and depressive symptoms. Accord-
ing to the CES-D, 69% (48 out of 70) were screened positive 
for depression.  
Analogue findings were shown by a cross-sectional study 
[6] on 59 SSc patients assessed by using the Patient Health 
Questionnaire depression scale (PHQ-9) to detect depressive 
disorders, HAQ for the health status and SF-36 for the qual-
ity of life. 77.4% of patients presented symptoms of depres-
sion: 61% had a major depressive syndrome, and 16.4% a 
minor depressive syndrome. The PHQ-9 score was signifi-
cantly higher in the patient with prolonged disease duration, 
severe joint pain, higher disease severity and activity. Also, 
depression had a negative impact on both physical and men-
tal SF-36 scores. 
Danieli and colleagues [12] published a cross-sectional 
study on 76 SSc patients aimed to evaluate health-related 
quality of life (HR-QOL) in patients with SSc, and to com-
pare it with that of patients with rheumatoid arthritis (RA). 
HR-QOL was evaluated by SF-36, SSc disease activity and 
severity by ACR criteria, disability by the Health Assess-
ment Questionnaire (HAQ), and depressive symptoms by the 
Beck Depression Inventory. While HR-QOL perception was 
not statistically different in patients with SSc and RA, com-
pared with RA, patients with SSc tended to perceive less 
bodily pain (p=0.06) and have less disability (p=0.04) but to 
report higher depressive symptom scores (p=0.05). SSc pa-
tients' HR-QOL was worse in patients with diffuse cutaneous 
involvement both in physical and in mental scores. 
Psychological distress and depression were both corre-
lated to physical health-related QoL, as shown by Hyphantis 
and colleagues in a cross-sectional study [41] on several 
chronic physical disorders, such as colorectal cancer (N = 
162), glaucoma (N = 100), rheumatoid arthritis (N = 168), 
systemic sclerosis (N = 56) and systemic lupus erythemato-
sus (N = 56), assessing psychological dimensions with the 
Symptom Distress Checklist (SCL-90) and health-related 
QoL with the WHO QoL Instrument, Short Form. Interest-
ingly, the SCL-90 somatization score was the only psycho-
logical distress covariate significantly correlated to physical 
HRQOL in all diseases (Betas between -0.33 and -0.49) ex-
cept in SSc, where depression was also a correlate.  
Another recent field of research is focused to investigate 
the association between clinical, psychopathological, and 
personality parameters in SSc patients, and their correlation 
with health related QoL. One of the most important parame-
ters taken into consideration by many studies on rheumatic 
diseases is the Sense of Coherence, the individual’s ability to 
experience life as understandable, meaningful and manage-
able, and to deal with problems arising. Sense of Coherence 
assessing gives a measure of an individual's resilience in the 
face of stress and capacity to cope with it. The most impor-
tant determinant for SOC is personal relationships, so in a 
prospective of health-promoting the Sense of Coherence may 
be enhanced to improve individual’s strength and skills to 
cope with diseases [42, 43]. 
High levels of psychological distress were found to be 
associated to disease duration and lower rates of Sense of 
Coherence in a study [44] on 56 SSc patients and 74 healthy 
controls, using the General Health Questionnaire, the Symp-
tom Distress Checklist-90-R, the Defense Style Question-
naire, the Sense of Coherence (SOC) Scale, and the Hostility 
and Direction of Hostility Questionnaire. Moreover, high 
rate of anxiety was found associated with arthritis-related 
painful conditions and SOC, while psychotic-like symptoms 
were only associated with age and a specific personality 
structure. Analogous finding was observed in RA patients, in 
which psychological distress mediated the correlation be-
tween psychological traits variants and physical health-
related QoL [45].  
Another study [46] compared arthritis-related pain and 
heath-related QoL in 57 SSc patients, 72 patients with rheu-
matoid arthritis, 43 with systemic lupus erytematosus, 34 
with Sjögren’s syndrome, and 74 healthy controls. Health-
related quality of life (HRQOL) was assessed using the 
World Health Organization Quality of Life Instrument, 
Short-Form (WHOQOL-BREF); other clinical information 
was obtained by the General Health Questionnaire, while the 
presence of psychological distress, the coping style and per-
sonality prevalent traits were detected using the Symptom 
Distress Check List, the Hostility and Direction of Hostility 
Questionnaire, the Defense Style Questionnaire, and the 
Sense of Coherence scale. HRQOL perceived by SSc pa-
tients was significantly impaired compared not only with 
healthy controls, but also in comparison with RA, SLE, and 
SS patients. Poorer HRQOL was founded associated with 
high level of psychological distress, maladaptive defenses, 
and lower sense of coherence 
Arat and colleagues focused a cross-sectional study [47] 
on a large cohort of SSc patients (N= 217: 49 with limited 
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with diffuse cutaneous SSc (dcSSc)) on illness perception 
and the ability to cope with physical and mental health prob-
lems. Illness perception and coping were assessed by the 
Revised Illness Perception Questionnaire and the Coping 
Orientation of Problem Experience inventory (COPE), 
health-related QoL was measured by the SF-36, and the rela-
tionship between illness perceptions and coping was exam-
ined using multiple linear regression analysis. Good physical 
health was significantly associated with the lcSSc subtype 
and low disease activity (p<0.01 and p<0.05, respec-
tively). The perception of 'serious consequences' and strong 
'illness identity' correlated with poor physical health 
(p<0.001). Good mental health was associated with low 
illness identity scores and low 'emotional response' scores 
(p<0.001). Interestingly, illness perception was found 
more significantly correlated with both physical and mental 
health than coping style, and appeared more important than 
classical disease symptoms to contribute to wellbeing of SSc 
patients and their health-related QoL. The importance of 
psychological traits, style of coping and adjustment of dis-
ease is underlined by Malcarne & Greenbergs, that analyzed 
8 types of coping strategies and found three types of coping 
as predictors of adjustment: Wishful Thinking, Blaming Self, 
and Problem-Focused Coping [48].  
An emergent question is represented by a possible cogni-
tive impairment in SSc patients. A dementia-like condition, 
in fact, may worsen psychiatric comorbidity and therapy 
compliance. Giuliodori and colleagues showed presence of 
reduced performance of executive functions in SSc patients, 
and, in absence of other apparent causes of cerebrovascular 
impairment, they hypothesized an alteration of cerebral per-
fusion regulation [49].  
DISCUSSION 
Mental health-related QoL is frequently impaired in SSc 
patients, and it could influence the general perception of 
quality of life, depending on a variety of cognitive-emotional 
variants related to the patient’s coping style. The high rate of 
depression seems to be strictly correlate with poor QoL, and 
this finding needs more research to establish if depression is 
due to a worse QoL or if it is the contrary, or if depression 
and quality of life impairment are both due to other disease 
related or inherent factors. Further studies, focusing on a 
common etiopathogenic hypothesis, should help clarify this 
topic.  
Another topic is the low rate of SSc patients with psychi-
atric comorbidity that receives an adequate treatment, despite 
the high frequency of depression and anxiety disorders and 
the availability of safe and manageable drugs. The burden of 
living with a chronic and painful illness, the fatigue, the dif-
ficulty in daily activities, and the disfiguration can give rise 
to demoralization, hopelessness, loss of self-worth, and ex-
pression of a wish to die. These facts appear intuitive and 
obvious, and sometimes may lead clinicians to prematurely 
assign a reactive explanation to the patient’s symptoms, and 
delay the start of a treatment.  
Patients’ point of view regarding their mental health-
related QoL could help physicians to enlarge the knowledge 
about physical and mental correlates of the disease, and to fit 
therapies as required by the patient. Particular attention must 
be given to informational needs [39]. Correct information, 
given by a rheumatologist, a dermatologist, a general practi-
tioner, and a psychologist or a psychiatrist may mitigate 
anxiety about the course of the disease, and enhance coping 
skills of patients. Catastrophizing and low Sense of Coher-
ence, both related to the depressive cognition and to worse 
QoL, are personality traits that could be modified. As previ-
ously discussed, efficacy coping styles are characterized by 
the skills of “seek for alliance”, “acquired self-
responsibility”, “think positive”. These coping skills can be 
trained by self-help groups, and in rare and disabling dis-
eases such as SSc, patients and relatives associations may 
help to change from a “illness-balanced medicine” to a “pa-
tient-balanced medicine”. Psychiatrist’s intervention, indis-
pensable in case of severe mental health impairment, may be 
postponed or replaced by self-help group or a supportive 
psychotherapy, directed to the knowledge of mechanisms to 
reduce stress response.  
For a rare disease such as SSc, Internet can be a powerful 
mass media, in which informations are easy to found, free 
and globalized [50]. Therefore, it may be desirable that phy-
sicians ask patients know about their disease, and what else 
they need to know. 
The heterogeneity of SSc, its seriousness, and the variety 
of its consequences on organs and systems required not only 
a multidisciplinary approach, but also an alliance between 
patients and health professionals.  
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